BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.nebraska.edu

Clinical Trials

Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics

Phase 4

Completed

Conditions: Genotype 1 Hepatitis C Virus

Interventions: Drug: harvoni

First Posted Date: 2016-05-03

Last Posted Date: 2023-12-29

Lead Sponsor: University of Nebraska

Target Recruit Count: 16

Registration Number: NCT02759861

Locations: 🇺🇸
University of Nebraska, Omaha, Nebraska, United States

Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women

Phase 2

Completed

Conditions: HIV
Contraception

Interventions: Drug: Levonorgestrel
Drug: Efavirenz

First Posted Date: 2016-03-30

Last Posted Date: 2024-10-03

Lead Sponsor: University of Nebraska

Target Recruit Count: 28

Registration Number: NCT02722421

Locations: 🇺🇬
Infectious Diseases Institute, Kampala, Uganda

The Lymphoid Tissue Pharmacology of Antiretroviral Drugs

Withdrawn

Conditions: HIV Infection

First Posted Date: 2016-03-14

Last Posted Date: 2023-08-24

Lead Sponsor: University of Nebraska

Registration Number: NCT02707926

Stress, Coping and Health Behaviors in Pregnancy

Completed

Conditions: Health Behaviors
Pregnancy
Coping
Stress

First Posted Date: 2016-03-10

Last Posted Date: 2023-11-28

Lead Sponsor: University of Nebraska

Target Recruit Count: 75

Registration Number: NCT02705235

Locations: 🇺🇸
Nebraska Medicine, Omaha, Nebraska, United States

Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation

Phase 2

Terminated

Conditions: Plasma Cell Myeloma

Interventions: Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation--CD34 HSCT
Procedure: Peripheral Blood Stem Cell Transplantation--AHSCT
Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation
Biological: Tetanus Toxoid Vaccine

First Posted Date: 2016-03-07

Last Posted Date: 2024-03-12

Lead Sponsor: University of Nebraska

Target Recruit Count: 8

Registration Number: NCT02700841

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Validation of a Revised Food Frequency Questionnaire

Completed

Conditions: Nutrition
Osteoporosis

Interventions: Other: Full length Block 2014 Food Frequency Questionnaire
Other: Revised Calcium, Vitamin D and Protein Screener

First Posted Date: 2016-02-26

Last Posted Date: 2023-09-29

Lead Sponsor: University of Nebraska

Target Recruit Count: 31

Registration Number: NCT02693184

Locations: 🇺🇸
Unversity of Nebraska Medical Center, Omaha, Nebraska, United States

Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit

Not Applicable

Completed

Conditions: Congenital CMV Infection

Interventions: Other: Education of parents to pursue prompt hearing screening.

First Posted Date: 2016-02-11

Last Posted Date: 2023-09-15

Lead Sponsor: University of Nebraska

Target Recruit Count: 60

Registration Number: NCT02680743

Locations: 🇺🇸
Nebraska Medicine Bellevue, Bellevue, Nebraska, United States
🇺🇸
Unversity of Nebraska Medical Center, Omaha, Nebraska, United States

Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy

Conditions: Epilepsy

First Posted Date: 2016-01-21

Last Posted Date: 2023-10-10

Lead Sponsor: University of Nebraska

Registration Number: NCT02660255

Locations: 🇺🇸
Unversity of Nebraska Medical Center, Omaha, Nebraska, United States

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Phase 2

Active, not recruiting

Conditions: Stage II Breast Cancer AJCC v6 and v7
Stage IIA Breast Cancer AJCC v6 and v7
Stage IIB Breast Cancer AJCC v6 and v7
HER2 Positive Breast Carcinoma
Stage I Breast Cancer AJCC v7
Stage IA Breast Cancer AJCC v7
Stage IB Breast Cancer AJCC v7

Interventions: Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Biological: Trastuzumab

First Posted Date: 2016-01-13

Last Posted Date: 2024-10-08

Lead Sponsor: University of Nebraska

Target Recruit Count: 20

Registration Number: NCT02654119

Locations: 🇺🇸
Nebraska Medicine-Village Pointe, Omaha, Nebraska, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Faith Regional Health Services Carson Cancer Center, Norfolk, Nebraska, United States

Optimal Lidocaine Buffering to Reduce Injection Pain in Local Anesthesia

Phase 4

Terminated

Conditions: Local Anesthesia

Interventions: Drug: lidocaine
Drug: sodium bicarbonate

First Posted Date: 2016-01-06

Last Posted Date: 2023-08-21

Lead Sponsor: University of Nebraska

Target Recruit Count: 70

Registration Number: NCT02647892

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy